Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP4 | P49662 | 1/20 | 0.34 |
| ▸ | CASP5 | P51878 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720470 | 0.91 | PDE4A (0.58) | PDE4APDE4BPDE4CPDE4DHRH1 | |
| SCHEMBL1719878 | 0.91 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL1719903 | 0.89 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL1719680 | 0.76 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL6397973 | 0.74 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DHTR2C | |
| SCHEMBL29824397 | 0.73 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL292710 | 0.73 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3321333 | 0.73 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DHRH1 | |
| SCHEMBL5200820 | 0.73 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DHTR2A | |
| SCHEMBL1720465 | 0.73 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819708-B1 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7648988-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-01-19 | — | — | US | disclosed |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | DOLLINGER HORST | 2008-06-26 | — | — | US | disclosed |
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116370-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4A 1428/4885PDE4B 1709/4885PDE4C 1814/4885 |
| US-20080153833-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | PDE4A 1428/4885PDE4B 1709/4885PDE4C 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.